HomeTrialNCT07364214
🔬NCT07364214Phase 1ACTIVE NOT RECRUITING

Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24)

Study Summary

The purpose of the study is to investigate the routes of elimination and overall mass balance of 100 mg quemliclustat containing 75 μCi \[14C\] following a single IV infusion of \[14C\]-quemliclustat in healthy adult male participants, and to quantify total radioactivity (TRA) in plasma, whole blood, urine, and feces.

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment8 participants
Primary Completion
Lead SponsorArcus Biosciences, Inc.
Data Retrieved2026-04-11 02:54:25.662752+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.